Intellia Therapeutics (NASDAQ:NTLA) CEO John Leonard Sells 34,146 Shares of Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John Leonard sold 34,146 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $314,484.66. Following the transaction, the chief executive officer directly owned 1,013,339 shares of the company’s stock, valued at approximately $9,332,852.19. This trade represents a 3.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA traded up $0.40 during mid-day trading on Wednesday, reaching $10.13. The company’s stock had a trading volume of 5,055,169 shares, compared to its average volume of 4,466,384. The stock has a 50-day moving average of $9.58 and a two-hundred day moving average of $12.70. The stock has a market capitalization of $1.17 billion, a P/E ratio of -2.37 and a beta of 2.05. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.10. The firm had revenue of $13.78 million for the quarter, compared to the consensus estimate of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The company’s quarterly revenue was up 51.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.34) EPS. Analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NTLA has been the topic of a number of recent analyst reports. Robert W. Baird set a $9.00 price objective on shares of Intellia Therapeutics in a report on Thursday, October 30th. Oppenheimer set a $27.00 price target on shares of Intellia Therapeutics in a report on Friday, November 7th. JMP Securities lowered their target price on shares of Intellia Therapeutics from $33.00 to $29.00 and set a “market outperform” rating on the stock in a research report on Tuesday, October 28th. Citigroup reaffirmed a “market outperform” rating on shares of Intellia Therapeutics in a research report on Tuesday, October 28th. Finally, Chardan Capital lowered their price objective on Intellia Therapeutics from $48.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Eleven equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $18.43.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. CIBC Bancorp USA Inc. acquired a new position in shares of Intellia Therapeutics during the 3rd quarter worth about $183,000. Danske Bank A S acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter worth $50,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Intellia Therapeutics in the 3rd quarter valued at approximately $30,000. Advisory Services Network LLC bought a new stake in Intellia Therapeutics during the third quarter worth $33,000. Finally, Kestra Private Wealth Services LLC bought a new stake in shares of Intellia Therapeutics during the 3rd quarter worth $608,000. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.